Cargando…
Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®
STW 5 (Iberogast®; Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany) contains nine plant extracts and possesses well-documented overall efficacy in functional gastrointestinal disorders (FGID). Little is known about the onset of symptom relief. Twenty-nine centers in Germany recruited 272 patie...
Autores principales: | Raedsch, Richard, Vinson, Bettina, Ottillinger, Bertram, Holtmann, Gerald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820387/ https://www.ncbi.nlm.nih.gov/pubmed/28744774 http://dx.doi.org/10.1007/s10354-017-0578-y |
Ejemplares similares
-
STW 5 (Iberogast(®))—a safe and effective standard in the treatment of functional gastrointestinal disorders
por: Ottillinger, Bertram, et al.
Publicado: (2012) -
Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
por: Madisch, Ahmed, et al.
Publicado: (2017) -
Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast
por: Abdel-Aziz, Heba, et al.
Publicado: (2017) -
Gastrointestinal Motility Disorders in Critically Ill
por: Govil, Deepak, et al.
Publicado: (2020) -
A Wireless Implant for Gastrointestinal Motility Disorders
por: Lo, Yi-Kai, et al.
Publicado: (2018)